Genomic Medicine, Biomarkers, and Health Sciences最新文献_第6页

Genomic Medicine, Biomarkers, and Health Sciences Pub Date : 2011-03-01 DOI: 10.1016/S2211-4254(11)60001-0

引用次数: 0

High-throughput Fluorescence Detections in Microfluidic Systems 微流体系统中的高通量荧光检测

Genomic Medicine, Biomarkers, and Health Sciences Pub Date : 2011-03-01 DOI: 10.1016/S2211-4254(11)60005-8

Shi-Wei Lin , Chih-Han Chang , Che-Hsin Lin

{"title":"High-throughput Fluorescence Detections in Microfluidic Systems","authors":"Shi-Wei Lin , Chih-Han Chang , Che-Hsin Lin","doi":"10.1016/S2211-4254(11)60005-8","DOIUrl":"10.1016/S2211-4254(11)60005-8","url":null,"abstract":"<div><p>High-throughput detection is always attractive for researchers in developing sensing techniques. Recently, MEMS techniques have become well-established to produce miniaturized microfluidic devices with low-cost and small size. However, large-scale conventional off-chip detection approaches may limit the throughput of the detection systems such that the benefits come with the miniaturization are hindered. This review gives a brief overview for the development of high-throughput detection techniques in microfluidic systems, especially for the major optically fluorescence detections. Fundamental fluorescence techniques and two microfluidic systems including the micro capillary electrophoresis and the micro flow cytometer are introduced in this review. Various approaches for developing high-throughput and parallel fluorescence detection in microfluidic system are reviewed. A state-of-the-art diascopic illumination system for multispectral analysis in microfluidic systems is also included. Even though great progress for high-throughput bio-analysis has been made during the past decades, there is plenty of room for further improving the performance of existing detection techniques.</p></div>","PeriodicalId":100577,"journal":{"name":"Genomic Medicine, Biomarkers, and Health Sciences","volume":"3 1","pages":"Pages 27-38"},"PeriodicalIF":0.0,"publicationDate":"2011-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2211-4254(11)60005-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77726995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Ha-ras Oncogene and Anticancer Drug Resistance Ha-ras癌基因与抗癌耐药

Genomic Medicine, Biomarkers, and Health Sciences Pub Date : 2011-03-01 DOI: 10.1016/S2211-4254(11)60006-X

Giri Raghavaraju , Hsiao-Sheng Liu

引用次数: 3

Prognostic and Molecular Factors in Stage II Colorectal Cancer II期结直肠癌的预后和分子因素

Genomic Medicine, Biomarkers, and Health Sciences Pub Date : 2011-03-01 DOI: 10.1016/S2211-4254(11)60002-2

Yung-Sung Yeh , Hwei-Ming Wang , Shiu-Ru Lin , Jaw-Yuan Wang

{"title":"Prognostic and Molecular Factors in Stage II Colorectal Cancer","authors":"Yung-Sung Yeh , Hwei-Ming Wang , Shiu-Ru Lin , Jaw-Yuan Wang","doi":"10.1016/S2211-4254(11)60002-2","DOIUrl":"10.1016/S2211-4254(11)60002-2","url":null,"abstract":"<div><p>Over the last 20 years, adjuvant chemotherapy has been administered after surgical resection of tumors for colorectal cancer (CRC) patients with stage III disease to reduce the risk of recurrence of cancer. However, it is controversial as to whether all stage II CRC patients, or at least stage II CRC patients with additional risk factors, should receive adjuvant chemotherapy. Adjuvant chemotherapy in stage II CRC patients may be considered for patients in high-risk groups. It is a high priority to define prognostic factors for these stage II CRC patients to identify high-risk patients at risk of tumor metastases or recurrence and referral of stage II CRC patients for individual assessment. Recent guidelines advocate the consideration of clinicopathological factors such as free bowel perforation or obstruction, lymphatic and vascular invasion, poorly differentiated tumors, fewer than 12 lymph nodes examined, tumors with adjacent organ involvement, and indeterminate or positive margins as strong predictors of a poor prognosis in stage II CRC. Furthermore, with recent advances in basic research attempting to elucidate the underlying molecular mechanisms of carcinogenesis, a variety of candidate genes with potential value for the early detection of cancer have been discovered. Molecular factors such as microsatellite stability and loss of heterozygosity of 18q have been used to identify groups of patients with stage II CRC who have much worse prognoses and may benefit from administration of chemotherapy. Accumulated reports have described the detection of circulating tumor cell-related molecular markers in the peripheral blood of CRC patients, which has important prognostic and therapeutic implications. Consequently, therapeutic decision-making models are likely to be further refined by the inclusion of such molecular markers.</p></div>","PeriodicalId":100577,"journal":{"name":"Genomic Medicine, Biomarkers, and Health Sciences","volume":"3 1","pages":"Pages 2-8"},"PeriodicalIF":0.0,"publicationDate":"2011-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2211-4254(11)60002-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74370322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Application of Embryonic Stem Cells on Parkinson's Disease Therapy 胚胎干细胞在帕金森病治疗中的应用

Genomic Medicine, Biomarkers, and Health Sciences Pub Date : 2011-03-01 DOI: 10.1016/S2211-4254(11)60004-6

Jenn-Rong Yang , Yu-Ting Lin , Chia-Hsin Liao

引用次数: 8